Skip to content

PrEP Demonstration Study in Swaziland

Expanding Options for HIV Prevention Through Pre-exposure Prophylaxis in Hhohho Region, Swaziland

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03254550
Enrollment
517
Registered
2017-08-18
Start date
2017-08-01
Completion date
2019-03-02
Last updated
2019-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Negative People Identified at Substantial Risk for HIV Infection

Keywords

PrEP

Brief summary

This stepped-wedge cluster-randomized trial is embedded in an 18-month observational cohort study that has the aim to assess the operationalization of oral Pre-Exposure Prophylaxis (PrEP) in Swaziland as an additional HIV combination prevention method among individuals at high risk of HIV infection. The trial aims to determine the effect of a healthcare facility-based PrEP promotion package on the number of clients who take up PrEP.

Detailed description

The study will assess who will be reached with an introduction to and an offer of PrEP - and who will take up PrEP - when PrEP becomes available through different delivery points in the public-sector health system, including outpatient department (OPD), antenatal care (ANC), postnatal care (PNC) , family planning (FP) , and following HIV counseling and testing (VCT). In addition to PrEP reach and PrEP uptake, the study aims to establish PrEP retention and average costs per client, by different health systems delivery points and to assess the effectiveness of a feasible and low-cost PrEP Promotion Package (PPP). The exact composition of PPP will be informed by findings from in-depth- interviews with clients, providers, and PrEP stakeholders. The effect of the PPP on the monthly number of clients who are initiated on PrEP will be studied using a stepped-wedge cluster-randomized design. Specifically, the trial will have two sequences with three healthcare facilities in each sequence, and three periods. In the first period, all healthcare facilities will be in the control phase; in the second period three healthcare facilities will implement the PPP; and in the third period all six healthcare facilities will implement the PPP.

Interventions

OTHERPrEP Promotion Package

A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge

Sponsors

Ministry of Health, Swaziland
CollaboratorOTHER_GOV
Heidelberg University
CollaboratorOTHER
Mylan Laboratories
CollaboratorINDUSTRY
World Health Organization
CollaboratorOTHER
Clinton Health Access Initiative Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Masking description

Healthcare facilities will not be informed as to when they are expected to start implementing the intervention (the PrEP Promotion Package) until two weeks prior to the start of the intervention phase.

Intervention model description

This is a stepped-wedge randomized design (there was no option for stepped-wedge design in the drop-down menu) with two sequences (each consisting of three healthcare facilities) and three periods.

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Confirmed HIV negative by rapid antibody test following the National HIV testing services (HTS) algorithm on the day of PrEP initiation * \> 16 years of age * Willing and able to provide written informed consent * Identified at substantial risk of acquiring HIV infection * No current or recent illness (within past month) consistent with acute HIV infection in combination with a preceding high risk exposure for HIV * No contraindications to the use of Tenofovir(TDF)/Lamivudine (3TC) * Ready to adhere to PrEP and willing to attend the follow up evaluations including repeat HIV testing and monitoring for side-effects

Exclusion criteria

* Younger than 16 years of age * Currently having symptoms of acute HIV infection * Suspicion of window period following a potential exposure to HIV * Body weight \< 40 kg * Creatinine clearance \<60 ml/min * Using other nephrotoxic drugs (e.g. aminoglycosides) * Not willing to come for follow up visits every 3 months which will include HIV testing and counselling and monitoring for side-effects.

Design outcomes

Primary

MeasureTime frameDescription
Uptake18 monthsThe monthly number of clients who was initiated on PrEP

Secondary

MeasureTime frameDescription
Substantial risk18 monthsThe monthly number of clients who was identified as being at a substantial risk of acquiring HIV
Acceptance conditional on risk18 months% of HIV-negative clients at substantial risk for HIV infection who accepted a PrEP offer
Risk assessment18 monthsThe monthly number of clients who underwent a risk assessment for PrEP eligibility
Retention at 6 months6 months% of clients taking PrEP who were retained at six months after PrEP initiation. Retention was defined as attending all follow-up visits during the first 180 days after PrEP initiation not more than seven days after the scheduled appointment.
HIV incidence18 month% of clients initiated on PrEP who seroconverted during the first six months after taking up PrEP.
Linkage12 monthsThe monthly number of clients who either took up PrEP or were linked to antiretroviral therapy

Countries

Eswatini

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026